AC IMMUNE APPOINTS EXPERIENCED LIFE SCIENCE PROFESSIONAL AS NEW CHIEF FINANCIAL OFFICER
24 November 2016 - 1:35AM
AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage
biopharmaceutical company focused on neurodegenerative diseases,
today announced that it has appointed Mr. Joerg Hornstein as Chief
Financial Officer effective Q1 2017. He replaces Mr. George Pavey,
who is leaving the Company after its recent successful IPO.
Martin Velasco, Chairman of the Board of
Directors of AC Immune, commented, "We thank Mr. Pavey for
his expertise in helping AC Immune achieve its IPO. As the Company
proceeds forward as a publicly-listed entity, with sustainable
growth plans, we are delighted to welcome Mr. Hornstein as our new
CFO. We will benefit from his extensive experience in the life
science industry, including senior financial, controlling and
accounting functions in Europe, Asia and the US."
About Joerg Hornstein Before
joining AC Immune, Mr. Hornstein served as Senior Vice President
Group Controlling for Unternehmensgruppe Theo Müller based in
Luxembourg. Between 2002 and 2013 he worked for Merck KGaA, a
leading science and technology company in healthcare, life science
and performance materials, where he held various senior finance
roles. Amongst others, he was CFO for Merck's operations in
Indonesia and Merck Serono's operations in China. Furthermore, he
served as Vice President Group Controlling for Merck Group
Headquarters in Germany and as Divisional CFO for Merck Millipore
in the US. Mr. Hornstein holds an MBA with Distinction from London
Business School, UK, and a Bachelor of Business Administration from
Baylor University, US.
AC Immune has established a detailed plan to
facilitate the transition from Mr. Pavey to Mr. Hornstein joining
the Company in Q1 2017.
About AC ImmuneAC Immune is a
clinical stage Swiss-based biopharmaceutical company focused on
neurodegenerative diseases with four product candidates in clinical
trials. The Company designs, discovers and develops therapeutic and
diagnostic products intended to prevent and modify diseases caused
by misfolding proteins. AC Immune's two proprietary technology
platforms create antibodies, small molecules and vaccines designed
to address a broad spectrum of neurodegenerative indications, such
as Alzheimer's disease. The Company's pipeline features seven
therapeutic and three diagnostic product candidates. The most
advanced of these is crenezumab, an anti-Abeta antibody in phase 3
clinical studies that is being advanced by the collaboration
partner Genentech, Inc., a wholly owned subsidiary of Roche. Other
business partners include Biogen, Janssen Pharmaceuticals, Nestlé
Institute of Health Sciences and Piramal Imaging.
Forward looking statementsThis
press release may contain statements that constitute
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Forward-looking statements are statements
other than historical fact and may include statements that address
future operating, financial or business performance or AC Immune's
strategies or expectations. In some cases, you can identify these
statements by forward-looking words such as "may," "might," "will,"
"should," "expects," "plans," "anticipates," "believes,"
"estimates," "predicts," "projects," "potential," "outlook" or
"continue," and other comparable terminology. Forward-looking
statements are based on management's current expectations and
beliefs and involve significant risks and uncertainties that could
cause actual results, developments and business decisions to differ
materially from those contemplated by these statements. These risks
and uncertainties include, but are not limited to, the timing and
conduct of clinical trials of AC Immune's product candidates, the
clinical utility of AC Immune's product candidates, the timing or
likelihood of regulatory filings and approvals, AC Immune's
intellectual property position and AC Immune's financial position.
These risks and uncertainties also include those described under
the captions "Risk Factors" and "Management's Discussion and
Analysis of Financial Condition and Results of Operations" in AC
Immune's Registration Statement on Form F-1 and other filings with
the Securities and Exchange Commission. Forward-looking
statements speak only as of the date they are made, and AC Immune
does not undertake any obligation to update them in light of new
information, future developments or otherwise, except as may be
required under applicable law. All forward-looking statements are
qualified in their entirety by this cautionary statement.
For further information please
contact:
Prof. Andrea PfeiferChief Executive OfficerPhone: +41-21-345 91
21E-mail:andrea.pfeifer@acimmune.com |
Eva SchierCorporate Communications ManagerPhone: +41-21-345 91
34Mobile: +41 79 926 66 03E-mail: eva.schier@acimmune.com
|
Nick Miles/ Toomas KullCabinet Privé de Conseils s.a.Phone :
+41 22 321 45 40E-mail : miles@cpc-pr.com
kull@cpc-pr.com |
In the USTed AgneThe Communications Strategy Group
Inc.Phone: +1 781 631 3117E-mail: edagne@comstratgroup.com
|
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/68f536e2-7d04-40b9-a54b-25ad0a21a251
AC Immune (NASDAQ:ACIU)
Historical Stock Chart
From Apr 2024 to May 2024
AC Immune (NASDAQ:ACIU)
Historical Stock Chart
From May 2023 to May 2024